Malaria
37 treatments and conditions followed through the public trial records. Not medical advice. How a status is set
Lists the pairs whose condition is this category or one beneath it. A category is not a diagnosis and not advice.
Broader: Infections
Narrower: Malaria, Falciparum 16, Malaria, Vivax 9
Treatments and conditions
| Treatment and condition | Where it stands | Trials |
|---|---|---|
| "Synchronised" arm (intervention) for malaria | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Artemether + Lumefantrine for malaria, vivax | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Artemether + Lumefantrine + TAFENOQUINE for malaria, vivax | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| artemether-lumefantrine for malaria, falciparum | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| artemether-lumefantrine + Mosquirixs for malaria, falciparum | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Atovaquone-Proguanil for malaria, falciparum | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Cabamiquine for malaria, falciparum | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Coartem® Baby for malaria | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Dihydroartemisinin + Piperaquine tetraphosphate for malaria, vivax | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Dihydroartemisinin + Piperaquine tetraphosphate + TAFENOQUINE for malaria, vivax | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Dihydroartemisinin-Piperaquine (DP) for malaria | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Etofenprox-treated lesu for malaria, falciparum | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Factory-treated lesu for malaria, falciparum | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| GSK malaria vaccine 257049 Vaccine for malaria | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ivermectin for malaria | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| M5717 200 mg + PYRONARIDINE for malaria, falciparum | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| M5717 330 mg + PYRONARIDINE for malaria, falciparum | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| M5717 500 mg + M5717 660 mg + PYRONARIDINE for malaria, falciparum | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| M5717 60 mg + PYRONARIDINE for malaria, falciparum | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| M5717 660mg + PYRONARIDINE for malaria, falciparum | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Malaria Vaccine 257049 for malaria | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Malaria Vaccine 257049 + Polio Sabin Oral Polio Vaccine (GSK) + TritanrixHepB/Hib for malaria | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Matrix-M with RH5.2 VLP and/or R21 for malaria, falciparum | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Methylenblue for malaria | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Mosquirixs for malaria, falciparum | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Permethrin-treated lesu for malaria | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Permethrin-treated lesu for malaria, falciparum | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Polio Sabin Oral Polio Vaccine (GSK) + TritanrixHepB/Hib for malaria | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Primaquine for malaria, vivax | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Pvs230D1-EPA/Matrix-M for malaria, vivax | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| R21 in Matrix- M adjuvant vaccine for malaria, falciparum | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| R21/Matrix-M - single vial formulation for malaria | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| R21/Matrix-M - two vial formulation for malaria | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Soaked lesu for malaria, falciparum | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Tafenoquine for malaria, vivax | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 6 |
| Tafenoquine + chloroquine for malaria, vivax | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Tafenoquine succinate for malaria, vivax | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
Categories are from Medical Subject Headings (MeSH), U.S. National Library of Medicine, courtesy of the U.S. National Library of Medicine: MeSH. They may not reflect the most current data available from NLM. NLM does not endorse this site.